News

Children’s National and Compremium partner on pediatric medtech innovation

Diagnosing pressure-related conditions without complicated, invasive procedures has long been a challenge in the medical community. Compremium’s technology aims to transform the diagnosis of pressure physiologies, including venous pressure, intracranial pressure, and tissue pressure conditions with their non-invasive, point of care solution. Through this strategic collaboration, Children’s National will serve as the Pediatric Innovation Hub for Compremium, leading clinical studies, research projects, and commercialization efforts focused on non-invasive pressure monitoring and other breakthrough technologies.

“This partnership is a pivotal step in advancing pediatric-specific technologies to address critical gaps in care,” said Kolaleh Eskandanian, PhD, MBA, vice president and chief innovation officer at Children’s National. “Compremium’s non-invasive, real-time pressure monitoring technology not only has the potential to transform pediatric care, but also demonstrates how prioritizing pediatric innovation can pave the way for broader adoption and scalability to adult populations.”

Initial area of focus will be the use of Compremium’s technology in congenital heart disease (CHD) patients. Pediatric cardiologists require frequent, non-invasive monitoring of central venous pressure (CVP) — a crucial measure of blood volume returning to the heart and overall circulatory function. Improved CVP data could provide new insights into cardiovascular health, potentially leading to better interventions and preventing long-term complications such as developmental delays and learning difficulties, which affect approximately 33% of CHD patients nationwide.

“Non-invasive CVP monitoring for the pediatric population is the holy grail of cardiac care, a long-awaited advancement that has the potential to revolutionize care,” said Yves d’Udekem, MD, PhD, chief of the Division of Cardiac Surgery at Children’s National. “Pediatric cardiac surgeons worldwide are eager for this breakthrough solution, which could transform how we monitor and treat cardiovascular patients. It’s exciting to see this innovation, and we are thrilled that Children’s National is leading the way in bringing it to children everywhere.”

“By integrating Compremium’s cutting-edge technology with AI-driven advancements, we aim to enhance accuracy, enable real-time data analysis, and provide predictive insights — critical capabilities for improving pediatric care” said Eskandanian. “Our pediatric providers are eager for innovative, child-friendly monitoring solutions that reduce the need for invasive procedures, and this collaboration is dedicated to making that a reality.”

For Compremium, this partnership marks an important milestone — its first major initiative in pediatric healthcare. “We are honored to collaborate with Children’s National Hospital,” said Vincent Baumann, CEO of Compremium AG. “This initiative allows us to accelerate and expand the clinical adoption of our solution, particularly for a vulnerable patient population.”

The collaboration agreement was led by Children’s National Innovation Ventures, the commercialization arm of Children’s National, dedicated to advancing regulated medical products that improve pediatric health. With a strong focus on industry partnerships, Innovation Ventures’ four core pillars focus on advancing pediatric-driven technologies, building strategic industry alliances, facilitating funding to de-risk and validate innovations, and managing intellectual property and licensing to drive commercialization — all by supporting both internal and external innovation to accelerate pediatric health solutions. Additionally, Innovation Ventures leads two federally-funded accelerator programs, supporting early-stage companies and academic teams in navigating regulatory, reimbursement, clinical, and commercialization pathways.

Read more here.

Recent News

06/02/2025

Virginia Tech researchers find promise in a new peptide drug to combat a deadly brain cancer

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer. In a study published May 16 in Cell Death and Disease, researchers identified a previously unknown trait of cancer cells that

05/28/2025

Brandy Salmon named Virginia Tech’s first vice president for innovation and partnerships

Brandy Salmon, who since 2017 has led Virginia Tech teams focused on connecting the university with corporations, foundations, and alumni worldwide has been named the university’s first vice president for innovation and partnerships. “True collaboration between higher education, government, and industry is essential for success in today’s evolving landscape,” said Virginia Tech President Tim Sands.

05/28/2025

Avera Joins Civica to Help Minimize Risk of Drug Shortages

Civica, a nonprofit pharmaceutical company created to prevent and mitigate drug shortages, announced today that Avera, a leading nonprofit healthcare provider in the Upper Midwest United States, has joined the company in helping protect patients from the impact of drug shortages of essential generic sterile injectable medicines. Drug shortages are a persistent challenge to the